Abstract:On December 14, 2006, the Food and Drug Administration (FDA) proposed two new regulations in the Federal Register amending current regulations governing expanded access to investigational drugs for treatment use and charging for investigational drugs. The proposals come at a time when FDA has found itself under new pressure to provide seriously ill patients with early access to investigational drugs outside the framework of clinical trials. In recent years, patient advocacy groups have filed citizen petitions with FDA asking the agency to provide specific criteria to patients and sponsors seeking expanded access or to create an early approval mechanism to permit easier access to investigational therapies. Further, FDA has seen proposed federal legislation intended to ensure early patient access to investigational treatments and nearly lost a lawsuit in federal court in which terminally ill patients sought a fundamental right of access to investigational therapies under the Due Process Clause of the Constitution. The proposed rules seek to assuage patient activists, physicians, drug sponsors and other critics who contend that FDA must strike an appropriate balance between allowing patient access to promising treatments while protecting against undue risk and safeguarding the clinical trials process. Although FDA heralded the announcement of the rules as a key step forward to improving patient access, the proposal does not expand access beyond measures currently available under longstanding agency practice and, in fact, creates new regulatory barriers and disincentives to industry participation in expanded access programs. This article examines the proposal in light of historical agency regulation and recent pressures to expand access. Section II describes the historical development of FDA's statutory authority to regulate drugs and the traditional new drug approval process. Section III describes the various methods through which FDA has allowed expanded access to investigational treatments since 1962. Section IV recounts various recent pressures on FDA to reform its expanded access procedures and describes the context in which FDA's recent proposal arises. Section V examines the changes proposed in both the proposed rules to expand access to investigational treatment and charging for investigational drugs. Section VI evaluates the rules and argues that the proposal will fail to expand access for patients because new restrictions on charging provide no incentive for industry participation and the proposed regulations create increased regulatory barriers to access inconsistent with FDA's statutory mandate

VA acquisition regulations: simplified acquisition procedures for health care resources--VA. Proposed rule

Third Party Billing for Medical Care Provided Under Special Treatment Authorities. Final rule

HIPAA administrative simplification: standards for electronic health care claims attachments. Proposed rule

Community Health Centers Could Provide Better Outsourced Primary Care for Veterans

Administrative simplification: adoption of operating rules for health care electronic funds transfers (EFT) and remittance advice transactions. Interim final rule with comment period

Comparing Complication Rates After Elective Total Knee Arthroplasty Delivered Or Purchased By The VA

TRICARE; sub-acute care program; uniform skilled nursing facility benefit; home health care benefit; adopting Medicare payment methods for skilled nursing facilities and home health care providers. Final rule

Purchasing High-Quality Community Nursing Home Care: A Will to Work With VHA Diminished by Contracting Burdens

FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform

Medicaid program; imposition of cost sharing charges under Medicaid--Health Care Financing Administration. Final rule with comment period

Health Care for Our Nation's Veterans: A Policy Paper From the American College of Physicians

Procurement in healthcare: Ensuring efficiency and compliance in medical supplies and equipment management

Administrative practices and procedures; promulgation of regulations for the efficient enforcement of law--FDA. Final rule

Solicitation of comments on the OIG/HCFA Special Advisory Bulletin on the patient anti-dumping statute--OIG and HCFA. Notice of proposed special advisory bulletin

Trends in Bundled Outpatient Behavioral Health Services in VA-Direct Versus VA-Purchased Care

Anatomy of an Acquisition Alternative: Leasing the Practice

A First Look at the VA MISSION Act Veteran Health Administration Medical School Scholarship and Loan Repayment Programs

Experiences with the Veterans' Choice Program

Medicare, Medicaid, and Maternal and Child Health Services Block Grant programs; civil money penalties and assessments for false or improper claims--Department of Health and Human Services. Notice of proposed rulemaking

Specialized due diligence called for on Medicare/Medicaid issues in health care acquisitions

HIPAA brings new requirements, new opportunities